Myelodysplastic syndrome with TP53 mutation is added in both classifications, recognising the poor prognosis associated with TP53 mutations.13 This subtype may be considered equivalent to AML for therapeutic considerations.14 Both classifications require ≥ 2 TP53 gene disruptions or a single TP53 mutation with VAF > 50%. Here, TP53 is linked to myelodysplastic syndrome.